This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Pays Up for ZymoGenetics

NEW YORK ( TheStreet) -- Bristol-Myers Squibb (BMY - Get Report) Tuesday said it's agreed to acquire ZymoGenetics (ZGEN) for an eye-popping 84% premium.

The deal values shares of ZymoGenetics, a Seattle-based biotech whose products in development include a Hepatitis C treatment, at $9.75 each. The stock closed Tuesday's session at $5.30, and was down 14% so far in 2010 prior to the announcement. ZymoGenetics's stock hasn't traded above $10 since March 2008.

Overall, the transaction is worth about $885 million. Net of ZymoGenetics' cash, the aggregate value of the deal is $735 million.

Bristol-Myers said the acquisition has already received the unanimous approval of the boards of both companies, and that shareholders representing roughly 37% of ZymoGenetics's outstanding common stock have entered agreements to support the deal and tender their shares to the offer.

"The acquisition of ZymoGenetics brings us full ownership of a promising investigational biologic that strengthens our very diversified Hepatitis C portfolio. Building on our leadership in virology, we are developing a strong portfolio to help patients with Hepatitis C," said Lamberto Andreotti, Bristol-Myers CEO, in a statement. "In addition, ZymoGenetics brings proven capabilities with therapeutic proteins and revenue from a marketed specialty surgical biologic."

Bristol-Myers expects the deal to dilute earnings by 3 cents a share in fiscal 2010 and 7 cents a share in fiscal 2011.

On August 3, ZymoGenetics posted a loss of $3.8 million, or 4 cents a share, for the second quarter ended in June with revenue totaling $37.7 million, up from $22.6 million in the same period a year earlier.

In addition to pegylated-interferon lambda, ZymoGenetics's novel interferon in Phase IIb development for the treatment of Hepatitis C, the company's products also include Recothrom, a recombinant thrombin approved for use as a topical hemostat to control non-arterial bleeding, and a number of early clinical and pre-clinical oncology and immunoscience programs.

-- Written by Michael Baron in New York.



>To contact the writer of this article, click here: Michael Baron.

>To submit a news tip, send an email to: tips@thestreet.com

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
BMY $64.67 -0.55%
AAPL $125.01 -0.63%
FB $78.10 0.70%
GOOG $524.22 -1.24%
TSLA $230.43 -1.08%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs